FASEB conference on Hematological Malignancies

描述（由申请人提供） 这是一份关于"血液学"会议部分资金的申请 在美国联合会的赞助下举行的“癌症” 实验生物学学会（FASEB），2001年7月28日至8月2日， 斯诺弥撒，科罗拉多。 将有十个主要会议和四个海报 sessions. 参与将限于155名科学家申请人，他们将 根据他们的专业知识和兴趣被选为最有可能 有助于创造一个激励和富有成效的环境。 在这些主题中， 包括讨论的是：产品的作用机制 染色体易位，细胞因子信号传导和酪氨酸磷酸化， 造血细胞，异常转录控制，细胞周期改变， 白血病细胞凋亡、分化和促有丝分裂途径的失调 和淋巴瘤，血液恶性肿瘤的基因组学，干细胞生物学， 翻译研究 使用动物模型系统分析 与白血病发展有关的基因的生物学功能， 淋巴瘤将是一个关键话题。 会议的一个主要目的是 遗传学家、生物化学家、分子生物学家和临床医生。 因此，会议将包括一次关于利用 新疗法的基本信息。 分析 造血系统肿瘤发生的潜在机制提供了一个 为在不同领域具有专业知识的基础科学家提供了独特的机会， 研究，与熟悉的临床医生交换意见， 与各种临床病症相关的表型。 从 在这次会议上交流的信息，新的研究途径已经出现 从过去的会议，和新的治疗策略的发展， 造血系统恶性肿瘤的治疗很可能出现在未来， 会议.

DESCRIPTION (provided by applicant) This is an application for partial funding of a Conference on "Hematological Malignancies" being held under the auspices of the Federation of American Societies for Experimental Biology (FASEB) from July 28 to August 2, 2001 at Sno Mass, Colorado. There will be ten major sessions and four poster sessions. Participation will be limited to 155 scientist applicants who will be selected on the basis of their expertise and interests as most likely to contribute to a stimulating and productive environment. Among the topics to be included for discussion are: mechanisms of action of the products of chromosomal translocations, cytokine signaling and tyrosine phosphorylation in hematopoietic cells, aberrant transcriptional control, cell cycle alterations, deregulation of apoptotic, differentiation and mitogenic pathways in leukemias and lymphomas, genomics of hematological malignancies, stem cell biology, and translational research. The use of animal models systems to analyze the biological functions of genes implicated in the development of leukemias and lymphomas will be a key topic. A major purpose of the meeting is to bring together geneticists, biochemists, molecular biologists and clinicians. Hence, the conference will include a session on potential ways to utilize basic information towards the formulation of novel therapies. Analysis of the mechanisms underlying the development of hematopoietic neoplasms provides a unique opportunity for basic scientists with expertise in distinct areas of research to exchange ideas with clinicians who are familiar with the phenotypes associated with the various clinical disorders. From the information exchanged in this conference, new avenues of research have emerged from past conferences, and the development of novel therapeutic strategies in the treatment of hematopoietic malignancies are likely to emerge from future meetings.